Condition: Sickle Cell Anemia · Sponsor: Children's Hospital Medical Center, Cincinnati
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.
This description comes directly from the study's public registry record.
Teresa Latham, DrPh · 513-803-7822 · Teresa.Latham@cchmc.org
Russell E Ware, MD, PhD · 513-803-4597 · Russell.Ware@cchmc.org
Always discuss trial participation with your own doctor first.
| Centro de Obstetricia y Ginecologia | Santo Domingo, Dominican Republic | Recruiting |
| Caribbean Institute for Health Research, University of West Indies | Kingston, Jamaica | Recruiting |
| Buganda Medical Centre | Mwanza, Tanzania | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07116772